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Objective: Cardiac irradiation during left-
sided breast radiotherapy may lead to dele-
terious cardiac side effects. Using image
guided radiotherapy, it is possible to exclude
the heart from treatment fields and monitor
reproducibility of virtual simulation (VS)
fields at treatment delivery using electronic
portal imaging (EPI). Retrospectively, we
evaluate the incidence of cardiac irradiation
at VS and subsequent unintended cardiac
irradiation during treatment.
Methods: Patients receiving left-sided radio-
therapy to the breast or chest wall, treated
with a glancing photon field technique during
a four-month period, were included. VS
images and EPIs during radiotherapy delivery
were visually assessed. The presence of any
portion of the heart within the treatment field
at VS or during treatment was recorded.
Central lung distance and maximum heart
distance were recorded.
Results: Of 128 patients, 45 (35.1%) had any
portion of the heart within the planned
treatment field. Of these, inclusion of the
heart was clinically unavoidable in 25
(55.6%). Of those with no heart included in
the treatment fields at VS, 41 (49.4%) had
presence of the heart as assessed on EPI
during treatment.
Conclusion: Unintended cardiac irradiation
during left-sided breast radiotherapy treat-
ment occurs in a sizeable proportion of
patients.
Advances in knowledge: Despite the use of
three-dimensional computed tomography
simulation and cardiac shielding, sizeable
proportions of patients receiving left-sided
breast cancer radiotherapy have unintended
cardiac irradiation.
Post-operative radiotherapy is indicated following
breast-conserving surgery and following mastectomy in
those with high-risk features [1]. Following breast-
conserving surgery, radiotherapy to residual breast tis-
sue has been shown to lead to a signiﬁcant reduction in
local recurrence rates, with an associated reduction in
breast cancer-speciﬁc mortality demonstrated in more
recent analyses [2]. For women at higher risk of re-
currence following mastectomy, such as those with
heavily node-positive disease, post-operative radiother-
apy also reduces local recurrence and improves survival
[2]. The acute toxicities of breast or chest wall radio-
therapy are well documented and usually resolve within
the ﬁrst few months following completion of treatment
[3,4]. Over recent years, there has been an increasing
awareness of the late effects of radiotherapy, particularly
when treatment is given in an adjuvant or radical setting
and long-term patient survival is anticipated [5,6].
Data from randomised trials have demonstrated excess
mortality from cardiovascular disease among women
treated with radiotherapy for early breast cancer, par-
ticularly where local nodal areas were irradiated [2,7].
A population-based study has also reported a signiﬁcant
association between fatal myocardial infarction and left-
sided adjuvant radiotherapy given post lumpectomy
[8]. During post-operative radiotherapy for breast
cancer, cardiac musculature and its associated vascula-
ture may be irradiated directly or indirectly via scatter
radiation. The risk of cardiovascular disease was shown
to be higher in those patients irradiated for a left-sided
breast cancer, although there is a suggestion that this
increased risk may not be present with newer radio-
therapy techniques [2,9–11]. Other studies report that
late cardiotoxicity still occurs with modern therapy
when patient follow-up is over 10 years [12].
The total dose to cardiac structures appears to affect the
degree of risk, although there is uncertainty as to the
identity of the critical structures. Animal studies have
shown the development of atherosclerotic changes in
irradiated cardiac vessels, with human post-mortem
examinations revealing similar changes, along with in-
creased ﬁbrotic change within cardiac tissue [8,13]. The
left anterior descending artery may be important as it
provides the blood supply to a signiﬁcant area of myo-
cardium, and ongoing studies are considering how the dose
to this, and to the other main coronary arteries, affects risk
of later cardiac events [14]. The a/b ratio for late effects
on the coronary vessels has not as yet been fully de-
termined, and the underlying radiobiology of heart damage
remains poorly understood [15]. In terms of cardiac
function, the most signiﬁcant pathological process is be-
lieved to be myocardial damage resulting from diffuse in-
terstitial ﬁbrosis secondary to a cytokine-driven acute
inﬂammatory response to radiation-induced endothelial
damage [16]. Fibrotic change reduces cardiac compliance,
and it may impair conduction pathways and lead to
valvular dysfunction. Radiation induced atherosclerosis
appears to be similar to atherosclerotic changes seen in
the unirradiated population, except that it may occur at
a younger age and in individuals without risk factors
typical for the development of coronary artery disease [17].
Although the current gold standard for calculating cardiac
dose is three-dimensional computed tomography (CT)
radiotherapy planning with manual contouring of cardiac
structures, this facility is not yet universally available in
UK radiotherapy centres. Taylor et al [14] recently dem-
onstrated that maximum heart distance (MHD) measured
on simulation images provides a reliable surrogate for
estimating dose to cardiac tissue. Using visual assessment
and measurement of MHD, we retrospectively evaluate
the incidence and extent of any cardiac irradiation at
virtual simulation (VS). As the volume of heart included
in radiation ﬁelds may change during treatment owing to
factors such as patient relaxation and interfractional and
intrafractional variation in respiration, we also evaluate
any subsequent unintended cardiac irradiation during
treatment using visual assessment and MHD measure-
ments from electronic portal imaging (EPI).
METHODS AND MATERIALS
In an institutionally approved study, all patients complet-
ing left-sided breast or chest wall radiotherapy during the
four-month period from October 2009 to February 2010
were selected. Baseline demographics including details of
surgical procedure, pathological tumour information and
systemic therapy received were obtained by retrospective
review of patient records. Details of prescribed radio-
therapy dosage and fractionation were recorded, including
details of any electron boost given to the tumour bed.
Simulation was performed in the supine position with
patients immobilised using a Med-TEC thorax immobili-
sation board and a knee rest (Med-TEC, Orange City, IA)
with both arms positioned above the head. VS was per-
formed using GE Advantage SIM software (GE Medical
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Systems, Milwaukee, WI). All patients were treated using
tangential pair irradiation with 6-MV photon beams.
Patients receiving whole breast radiotherapy following
breast-conserving surgery were treated with divergence-
matched tangential ﬁelds. Half beam blocking was used in
cases of chest wall radiotherapy post-mastectomy. Irradi-
ation of the ipsilateral supraclavicular fossa with a direct
anterior ﬁeld was included in patients with four or more
positive axillary nodes at surgery as per the departmental
protocol. Our protocol also states that “the heart should be
excluded from the treatment ﬁeld, except in cases with
close or involved deep margins, where modiﬁcation of the
planning target volume to avoid the heart may lead to
suboptimal coverage of the margins at risk”. It was at the
treating clinician’s discretion whether to modify the treat-
ment ﬁeld boundaries or create custom cardiac shielding
with multileaf collimators (MLCs) in cases where the heart
was included in the treatment ﬁeld unnecessarily.
VS CT and digitally reconstructed radiograph (DRR)
images for each patient were visually assessed by a thera-
peutic radiographer and clinical fellow in clinical oncology
to determine if there was inclusion of the heart at treat-
ment simulation. This assessment was undertaken jointly
for each patient and agreement reached between the two
observers for each of the parameters recorded. Central
lung distance (CLD) and MHDwere measured. The MHD
has been deﬁned as “the maximum distance between the
anterior cardiac contour and the posterior tangential ﬁeld
border” [14] and is demonstrated in Figure 1.
Electronic portal images (EPIs) were obtained on Days 1, 2
and 3 of treatment and once weekly thereafter as per de-
partmental policy. An EPI with a cine loop during treat-
ment delivery was obtained on Day 3. All EPIs, including
each frame from the Day 3 cine images, were assessed by
the same therapeutic radiographer and clinical fellow who
had interpreted the DRRs. The presence of any portion of
the heart within the treatment ﬁeld was recorded and CLD
and MHD were measured for each image, with the two
observers reaching a consensus for each measurement.
Pathological information regarding surgical margins was
analysed for any patient where there was inclusion of the
heart within the treatment ﬁeld on one or more recorded
images to assess any potential reasons for inclusion of the
heart within the treatment ﬁeld. A signiﬁcance level of
0.05 was used. Pearson’s correlation coefﬁcient (r) was
used to assess the signiﬁcance of any correlation, the t test
was used to estimate differences between mean values
and the x2 test was used to compare categorical data
between two independent groups of data. Calculations
were performed using SPSS® v. 15.0.1.1 (SPSS, Chicago,
IL). Descriptive statistics were used where appropriate.
RESULTS
132 patients were identiﬁed as having received left-sided
radiotherapy for breast cancer during the study period. In
one of these patients, the treatment was palliative in in-
tent, the remainder received adjuvant radiotherapy fol-
lowing primary breast surgery. Full data were available for
analysis in 128 patients; there was one male patient, and
the median age at time of radiotherapy was 58.5 years,
with a range of 29–87 years. 94 (73%) patients had breast-
conserving surgery. As adjuvant therapy, 45 patients re-
ceived an anthracycline-based adjuvant chemotherapy
regimen, and eight were to receive adjuvant trastuzumab
for 12 months following radiotherapy. The majority of
patients (61%) were treated with a hypofractionated
regimen of 40Gy in 15 daily fractions, with the re-
mainder receiving 50Gy in 25 daily fractions. An electron
boost to the tumour bed was delivered to 39 patients.
Of the 128 patients analysed, 45 (35.1%) had any
portion of the heart included within the planned
treatment ﬁeld at simulation. For 25 of the 45 patients
who had inclusion of the heart at simulation, inclusion
of the heart was clinically unavoidable owing to close or
involved surgical margins. Of the 83 patients for whom
there was no inclusion of the heart within the treatment
ﬁelds at simulation, 41 had evidence of the heart within
treatment ﬁelds during radiotherapy delivery as
assessed on EPIs obtained during treatment. This
accounted for 32% of all patients assessed; therefore,
almost one-third of the study group received un-
intended cardiac irradiation. Of note, of the 45 patients
Figure 1. Maximum heart distance and central lung
distance as viewed on electronic portal imaging during
radiotherapy treatment.
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Figure 2. (a) Histogram illustrating the average (mean) measurement of the maximum heart distance (MHD)
recorded for each patient during treatment as assessed on electronic portal imaging (EPI) and the associated MHD
as measured on the digitally reconstructed radiograph (DDR) at simulation for each patient. The patients have been
sorted in order of descending average MHD during treatment. (b) Histogram illustrating the average (mean)
measurement of the MHD recorded during treatment as assessed on EPI and the associated MHD as measured on the
DDR at simulation for each patient. The patients have been sorted in order of descending MHD at simulation.
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with the heart present at simulation, only 1 patient had
no heart present as observed on EPI during treatment.
83 of the total 128 patients in this study had presence of
the heart within the treatment ﬁelds as visualised on EPI
at some point during their treatment. For all patients the
mean MHD as measured on EPI was 3.9mm (range
0–20.3mm). The results for MHD at simulation and the
average MHD during treatment for all patients are il-
lustrated in Figure 2. Table 1 summarises the MHD
results and associated treatment characteristics. In those
patients with the heart included in the treatment ﬁelds at
simulation, the heart was present during treatment in
91% of EPIs, with an average MHD of 8.36mm [stan-
dard error (SE) 60.51]. For those patients with no heart
included at simulation but in whom the heart was
present during treatment, the heart was present in
67.8% of EPIs, with an average MHD of 3.87mm (SE
60.51), which was signiﬁcantly different from those
with the heart present at simulation (p50.0001). For all
patients, and as expected, there was a signiﬁcant posi-
tive correlation between MHD and CLD (Pearson’s
correlation r50.525, p,0.001), and interfractional motion
was observed. Sizeable intrafractional motion was also
detected on review of Day 3 cine loop EPIs (Figure 3).
Comparing those patients who received radiotherapy
following breast-conserving surgery with those who re-
ceived radiotherapy after mastectomy, there was no sig-
niﬁcant difference in cardiac involvement between these
subsets of patients (Table 2). To assess the variation in
cardiac irradiation over the duration of a patient’s
treatment, the MHD as measured on the Day 1 EPI was
compared with the MHD on the last EPI image acquired
for all patients (n5128). On Day 1, 66 patients had any
degree of cardiac irradiation as compared with 64 patients
at the last cine image. The average MHD on Day 1 was
4.36 (SE 60.49) and this fell signiﬁcantly to 3.72 (SE
60.42) (p50.033, two-tailed). There was strong positive
correlation between the Day 1 and the last day EPI MHD
measurements (Pearson’s correlation r50.791, p,0.001).
All 41 of the subgroup of patients who had evidence of
unintentional cardiac irradiation as determined from EPI
assessment were female. All received radiotherapy as an
adjuvant treatment, three patients for a diagnosis of ductal
carcinoma in situ and the remainder for invasive breast
carcinoma. Seven patients, out of the total 128 patients, had
custom cardiac shielding with MLCs designed at simula-
tion. Six of these patients with custom cardiac shielding
had complete avoidance of the heart on simulation images;
however, four of these six patients had presence of the
heart within the treatment ﬁeld when EPIs were assessed.
DISCUSSION
In our study population, 35% of patients had planned
inclusion of the heart within the treatment ﬁeld. In
more than half of these cases, irradiation of a portion of
the heart was unavoidable owing to close or involved
surgical margins. Determination of the reason for in-
clusion of the heart within the treatment ﬁelds at
simulation in the remainder of this patient group is out-
side the scope of our study. Of those patients whose
radiotherapy plan avoided inclusion of the heart at
simulation, 49% had unintended irradiation of the
heart during treatment on review of EPIs recorded
during treatment. Given the concerns regarding long-
term cardiac toxicity from treatment, and that these
risks may still be present with newer radiotherapy
techniques, it is imperative that any dose to cardiac
structures is minimised during adjuvant radiotherapy.
This is particularly important as the increasing use of
other cardiotoxic agents, such as anthracycline-based
chemotherapy and trastuzumab as part of adjuvant
Table 1. Average maximum heart distance (MHD) during treatment groupings and associated relevant treatment
characteristics
Average
MHD
Number of
patients (n)
Number of patients
with
breast-conserving
surgery n (%)
Number of
patients with
heart present at
simulation
n (%)
Number of
patients treated
with 3-week
fractionation
n (%)
Number of
patients treated
with a 5-week
fractionation
n (%)
0.0–4.9mm 85 67 (78.8) 15 (17.6) 61 (71.8) 24 (28.2)
5.0–9.9mm 29 18 (62.1) 18 (62.1) 10 (34.4) 19 (65.5)
10.0–25.0mm 14 9 (64.3) 12 (85.7) 7 (50) 7 (50)
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therapy, may increase the risk of cardiotoxicity [6]. Our
study highlights that a sizeable proportion of patients
receive unintended cardiac irradiation. We suggest that
in patients with left-sided breast cancers requiring ad-
juvant radiotherapy consideration should be given to
advanced practice methods that allow direct cardiac
irradiation to be reduced or avoided.
In our centre, the use of breast boards for simulation and
treatment is standard practice. These simple devices are
estimated to reduce mean cardiac dose by around 60%,
and they also reduce by four times the cardiac volume
that falls within the 50% isodose when compared with
the use of a ﬂat couch [18,19]. Delivering radiotherapy
only when the patient is in deep inspiration with aid of
a respiratory gating device has also been shown to
signiﬁcantly reduce the volume of cardiac tissue irradi-
ated [20]. Use of the lateral decubitus position for elec-
tron boost ﬁelds may reduce dose to critical organs,
including the heart and lungs [21]. Intensity modulated
radiotherapy (IMRT) is gaining increasing acceptance
as a treatment technique in many disease sites and is
becoming more widely available within the UK [22,23].
Its application in adjuvant breast radiotherapy has been
studied with regard to impact on cardiac irradiation, and
it has been reported that the use of IMRT leads to
a signiﬁcant reduction in maximal dose to the left ven-
tricle, which Lohr et al. believe could lead to a signiﬁcant
reduction in cardiac mortality [24]. IMRTmay, however,
lead to a larger volume of cardiac tissue receiving lower
doses of radiation than conventional planning [24].
Given the continued uncertainty regarding the identity
Figure 3. Intrafraction motion for individual patients based on Day 3 cine image analysis. The range between the
maximum and the minimum value for central lung distance (CLD) and the mean maximum heart distance (MHD) as
viewed on the Day 3 cine images was used to provide a measure of intrafractional motion for each patient. The
scatter plot illustrates the intrafractional motion values for each case, with the mean values denoted.
Table 2. Impact of surgery type on the presence of the heart at simulation and during treatment
Presence of heart at simulation/
during treatment
Mastectomy
Breast-conserving
surgery Significance of difference
between groups
n (%) n (%)
Heart present during
simulation
Yes 11 (37.9) 31 (33.0)
p50.623
No 18 (62.1) 63 (67.0)
Heart present during treatment
Yes 21 (72.4) 60 (63.8)
p50.394
No 8 (27.6) 34 (36.2)
Cardiac irradiation in breast cancer
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of the critical cardiac structures and appropriate dose
constraints, further outcome data will be needed to as-
sess the impact of IMRT on cardiac mortality.
Prone positioning is another potential treatment tech-
nique that may minimise dose to cardiac tissues. However,
in a dosimetric study of prone radiotherapy where the
impact of prone planning on heart and left anterior
descending coronary artery doses was assessed, the impact
of prone planning was variable. The effect of prone
planning appeared to be dependent on the size of the
breast tissue irradiated. A signiﬁcant reduction in heart
doses was seen in women with a larger breast volume and
an increase in the dose to the heart observed in women
with a smaller breast volume when the prone plans were
compared with a supine planning technique [25]. An
interesting ﬁnding from our study is the change in MHD
during treatment with a signiﬁcant reduction between the
ﬁrst and the last EPI MHD measurements. Perhaps, this
may be a result of patient relaxation as treatment pro-
gresses, which may in turn be having the effect of posi-
tioning of the heart away from the treatment ﬁeld. This
ﬁnding may also reﬂect a reduction in respiratory motion
amplitude as the patient relaxes, with the potential effect
of reducing the amount of heart receiving treatment. The
impact of strategies to help patients relax during treatment
and thus improve patient alignment during treatment
could be the focus of separate investigation.
In our study, good correlation between MHD and CLD
was observed. This suggests that the MHD measurement
of the proportion of the heart within the treatment ﬁeld
is feasible, and the correlation with CLD, which is an
established method of assessing patient set-up during
treatment, gives some reassurance that visual assessments
of cardiac inclusion performed well. Both interfractional
and intrafractional motion was observed, as evidenced by
the mean range of both CLD and MHD illustrated in
Figure 3. This has implications for the delivery of treat-
ments that employ cardiac shielding. This suggests that, to
attain the beneﬁt of cardiac shielding, treatment must be
subsequently delivered with assessment of daily patient
set-up, the ability to correct for set-up errors and some
management of respiratory motion.
The inclusion of modest patient numbers treated only in
one centre is a limitation of our study. Although only
two members of staff assessed the EPIs from each patient
with the potential bias this may introduce, it was hoped
that joint recording would minimise interobserver vari-
ation and improve consistency of recording. A further
limitation is that a signiﬁcant proportion of patients had
only a small MHD included within the radiotherapy
treatment ﬁeld, and the clinical signiﬁcance of inclusion
of small parts of the heart is not fully understood [26].
Finally, although the MHD has been demonstrated in
a previous study to provide a reliable surrogate for es-
timation of the dose to cardiac structures, our study did
not include a calculation of the actual dose delivered to
the cardiac structures during treatment [14]. It is also
important to note that the use of MHD to predict for
mean heart dose has been demonstrated only in women
with no cardiac shielding. Seven patients in our study
group had custom cardiac shielding created at simula-
tion, and the use of MHD cannot therefore be assumed
to be applicable to these patients. In the further inves-
tigation of unintended cardiac irradiation during treat-
ment, images collected from cone beam imaging may
permit a more accurate dose assessment than those
gleaned from EPIs, and this may be a focus of further
investigation.
CONCLUSION
Despite the exclusion of the heart from direct irradia-
tion at radiotherapy treatment planning, a sizeable
proportion of patients had unintended cardiac irradi-
ation in this study. Advanced treatment techniques that
permit reproducible cardiac shielding during breast
radiotherapy treatments should be considered for pa-
tients with left-sided breast cancers.
REFERENCES
1. National Institute for Health and
Clinical Excellence. NICE Clinical
Guideline 80. Early and locally
advanced breast cancer: diagnosis
and treatment. NICE, 2009 [accessed
16 June 2012]. Available from: http://
www.nice.org.uk/nicemedia/live/
12132/43312/43312.pdf
2. Clarke M, Collins R, Darby S,
Davies C, Elphinstone P, Evans E,
et al. Effects of radiotherapy and of
differences in the extent of surgery
R B Goody, J O’Hare, K McKenna et al
7 of 8 bjr.birjournals.org Br J Radiol;86:20120434
for early breast cancer on local
recurrence and 15-year survival: an
overview of the randomized trials.
Lancet 2005;366:2087–106.
3. Whelan TJ, Levine M, Julian J,
Kirkbride P, Skingley P. The effects
of radiation therapy on quality of
life of women with breast carci-
noma: results of a randomized trial.
Ontario Clinical Oncology Group.
Cancer 2000;88:2260–6.
4. Fiets WE, van Helvoirt RP, Nortier
JWR, van der Tweel I, Struikmans
H. Acute toxicity of concurrent
adjuvant radiotherapy and chemo-
therapy (CMF or AC) in breast
cancer patients. A prospective,
comparative, non-randomised
study. Eur J Cancer 2003;39:1081–8.
5. Lind P. Clinical relevance of pul-
monary toxicity in adjuvant breast
cancer irradiation. Acta Oncol
2006;45:13–15.
6. Healey Bird BRJ, Swain SM. Cardiac
toxicity in breast cancer survivors:
review of potential cardiac problems.
Clin Cancer Res 2008;14:14–24.
7. Early Breast Cancer Trialists’ Col-
laborative Group. Favourable and
unfavourable effects on long-term
survival of radiotherapy for early
breast cancer: an overview of the
randomized trials. Lancet 2000;355:
1757–70.
8. Paszat LF, Mackillop WJ, Groome
PA, Schulze K, Holowaty E. Mor-
tality from myocardial infarction
following postlumpectomy radio-
therapy for breast cancer: a popu-
lation-based study in Ontario,
Canada. Int J Radiat Oncol Biol
Phys 1999;43:755–62.
9. Paszat LF, Mackillop WJ, Groome
PA, Boyd C, Schulze K, Holowaty E.
Mortality from myocardial infarction
after adjuvant radiotherapy for breast
cancer in the surveillance, epidemi-
ology, and end-results cancer regis-
tries. J Clin Oncol 1998;16:2625–31.
10. Darby S, McGale P, Peto R, Granath
F, Hall P, Ekbom A. Mortality from
cardiovascular disease more than
10 years after radiotherapy for
breast cancer: nationwide cohort
study of 90 000 Swedish women.
BMJ 2003;326:256–7.
11. Woodward WA, Strom EA, McNeese
MD, Perkins GH, Outlaw EL,
Hortobagyl GN, et al. Cardiovascu-
lar death and second non-breast
cancer malignancy after postmas-
tectomy radiation and doxorubicin-
based chemotherapy. Int J Radiat
Oncol Biol Phys 2003;57:327–35.
12. Demirci S, Nam J, Hubbs JL,
Nguyen T, Marks LB. Radiation-
induced cardiac toxicity after ther-
apy for breast cancer: interaction
between treatment era and follow-
up duration. Int J Radiat Oncol
Biol Phys 2009;73:980–7.
13. Gyenes G. Radiation-induced ische-
mic heart disease in breast cancer—
a review. Acta Oncol 1998;37:241–6.
14. Taylor CW, McGale P, Povall JM,
Thomas E, Kumar S, Dodwell D,
et al. Estimating cardiac exposure
from breast cancer radiotherapy in
clinical practice. Int J Radiat Oncol
Biol Phys 2009;73:1061–8.
15. Stewart JR, Fajardo LF, Gillette SM,
Constine LS. Radiation injury to
the heart. Int J Radiat Oncol Biol
Phys 1995;31:1205–11.
16. Rodemann HP, Bamberg M. Cellu-
lar basis of radiation-induced ﬁbro-
sis. Radiother Oncol 1995;35:83–90.
17. Basavaraju SR, Easterly CE. Patho-
physiological effects of radiation on
atherosclerosis development and
progression, and the incidence of
cardiovascular complications. Med
Phys 2002;29:2391–403.
18. Canney PA, Deehan C, Glegg M,
Dickson J. Reducing cardiac dose in
post-operative irradiation of breast
cancer patients: the relative impor-
tance of patient positioning and CT
scan planning. Br J Radiol 1999;72:
986–93.
19. Canney PA, Sanderson R, Deehan C,
Wheldon T. Variation in the proba-
bility of cardiac complications with
radiation technique in early breast
cancer. Br J Radiol 2001;74:262–5.
20. Korreman SS, Pedersen AN,
Nottrup TJ, Specht L, Nystrom H.
Breathing adapted radiotherapy for
breast cancer: comparison of free
breathing gating with the breath-
hold technique. Radiother Oncol
2005;76:311–18.
21. Ludwig MS, McNeese MD, Buch-
holz TA, Perkins GH, Strom EA.
The lateral decubitus breast boost:
description, rationale, and efﬁcacy.
Int J Radiat Oncol Biol Phys 2010;
76:100–3.
22. Staffurth J. A review of the clinical
evidence for intensity-modulated
radiotherapy. Clin Oncol (R Coll
Radiol) 2010;22:643–57.
23. Mayles WP. Survey of the availability
and use of advanced radiotherapy
technology in the UK. Clin Oncol
(R Coll Radiol) 2010;22:636–42.
24. Lohr F, El-Haddad M, Dobler B,
Grau R, Wertz HJ, Kraus-Tiefen-
bacher U, et al. Potential effect of
robust and simple IMRT approach
for left-sided breast cancer on
cardiac mortality. Int J Radiat
Oncol Biol Phys 2009;74:73–80.
25. Kirby AM, Evans PM, Donovan EM,
Convery HM, Haviland JS, Yarnold
JR. Prone versus supine positioning
for whole and partial-breast radio-
therapy: a comparison of non-target
tissue dosimetry. Radiother Oncol
2010;96:178–84.
26. Sardaro A, Petruzzelli MF, D’Errico
MP, Grimaldi L, Pili G, Portaluri M.
Radiation-induced cardiac damage in
early left breast cancer patients: risk
factors, biological mechanisms, radio-
biology, and dosimetric constraints.
Radiother Oncol 2012;103:133–42.
Cardiac irradiation in breast cancer
8 of 8 bjr.birjournals.org Br J Radiol;86:20120434
